Literature DB >> 6430440

Role of glucocorticoids in management of malignant hypercalcaemia.

R C Percival, A J Yates, R E Gray, F E Neal, A R Forrest, J A Kanis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6430440      PMCID: PMC1442158          DOI: 10.1136/bmj.289.6440.287

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  2 in total

1.  Rehydration in the treatment of severe hypercalcaemia.

Authors:  D J Hosking; A Cowley; C A Bucknall
Journal:  Q J Med       Date:  1981

Review 2.  The hypercalcemia of malignancy: pathogenesis and management.

Authors:  G R Mundy; T J Martin
Journal:  Metabolism       Date:  1982-12       Impact factor: 8.694

  2 in total
  12 in total

1.  Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy.

Authors:  S Fatemi; F R Singer; R K Rude
Journal:  Calcif Tissue Int       Date:  1992-02       Impact factor: 4.333

Review 2.  Palliative medicine.

Authors:  R J George; A L Jennings
Journal:  Postgrad Med J       Date:  1993-06       Impact factor: 2.401

Review 3.  Hypercalcaemia in malignancy.

Authors:  D A Heath
Journal:  BMJ       Date:  1989-06-03

4.  Malignant hypercalcaemia.

Authors:  J C Stevenson
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-17

Review 5.  Medical management of hypercalcaemia.

Authors:  S H Ralston
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

Review 6.  Current management of malignant hypercalcaemia.

Authors:  J C Stevenson
Journal:  Drugs       Date:  1988-08       Impact factor: 9.546

7.  Effect of single high dose infusions of aminohydroxypropylidene diphosphonate on hypercalcaemia caused by cancer.

Authors:  B M Cantwell; A L Harris
Journal:  Br Med J (Clin Res Ed)       Date:  1987-02-21

Review 8.  Hypercalcaemia of malignancy.

Authors:  P J Kelly; J A Eisman
Journal:  Cancer Metastasis Rev       Date:  1989-06       Impact factor: 9.264

Review 9.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 10.  The risks and benefits of corticosteroids in advanced cancer.

Authors:  R Twycross
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.